Antisoma starts phase IIb trial of AS1411
Antisoma has started a randomised, controlled, multi-territory, phase IIb trial of AS1411 in patients with acute myeloid leukaemia.
AstraZeneca PLC on Monday reported a positive result in a Phase III study of its thyroid cancer drug.